Clinical trial · Observational
CoSMAP Trial: SP-EA vs MP-TA Robot-Assisted Radical Prostatectomy
Comparison of Perioperative and Postoperative Outcomes of Single-port (SP) Extraperitoneal Approach and Multi-port (MP) Transperitoneal Approach in Robot-assisted Radical Prostatectomy：A Propensity Score-matched Retrospective Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 18, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260918-000001
Summary
Brief summary (as posted)
This multicenter retrospective observational study aims to compare perioperative and postoperative outcomes between the da Vinci SP extraperitoneal approach (SP-EA) and the robotic multi-port transperitoneal approach (MP-TA) in robot-assisted radical prostatectomy for localized prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- SP-EA group
- description
- Patients who underwent robot assisted radical prostatectomy using the da Vinci SP extraperitoneal approach.
- label
- MP-TA group
- description
- Patients who underwent robot assisted radical prostatectomy using the robotic multi port transperitoneal approach.
Primary outcomes (2)
- measure
- Incidence of postoperative complications and Clavien-Dindo Grade 3a or higher postoperative complications
- timeFrame
- Within 6 and 12 months after surgery
- description
- Postoperative complications occurring after robot assisted radical prostatectomy, including complications classified as Clavien-Dindo Grade 3a or higher.
- measure
- Urinary continence rate
- timeFrame
- Within 6 and 12 months after surgery
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: 1. Patients with localized prostate cancer (clinical stage T1-T3a, N0, M0) eligible for radical prostatectomy 2. Patients who underwent RARP via SP-EA or MP-TA on or after January 1, 2023 3. Patients with available postoperative follow-up data for ≥6 months (≥166 days) \*note 1) Exclusion Criteria: 1. Patients who have expressed an intention to refuse the use of their data for this study 2. Patients who underwent RARP using surgical approaches other than those specified in the inclusion criteria (e.g., transvesical approach) 3. Patients who underwent RARP with pelvic lymph node dissection (PLND) 4. Patients with a history of radiotherapy for prostate cancer 5. Any other patients whom the principal investigator or a co-investigator deem inappropriate, such as those with missing outcome data.
References
Publications (0)
Data not yet available